Abstract | BACKGROUND: METHODS: The subjects were 20 advanced ICC patients treated using subcutaneous PEG-IFNα-2b (50-100 μg on day 1 of every week, for 4 weeks) and intra-arterial infusion of 5-FU (250 mg/day for 5 h on days 1-5 of every week, for 4 weeks). One treatment cycle lasted 4 weeks. Therapy was discontinued in patients with progressive disease (PD). For responses other than PD, treatment was repeated for ≥1 cycle. RESULTS: The objective early response rate was 60.0 %. Cumulative survival rates were 71.6 % at 6 months, 53.7 % at 12 months, 28.6 % at 18 months, and 14.3 % at 24 months. Median survival time was 14.6 months. All adverse reactions were controllable by temporary suspension of treatment. Serious complications and treatment-related deaths were not observed. CONCLUSIONS: The combination therapy of PEG-IFNα-2b and 5-FU for advanced ICC seems not to be worse than the results of the previous studies. Furthermore, most adverse effects are transient and well tolerated. Based on the present findings, this combination therapy may be useful for patients with advanced ICC as one of the therapeutic option.
|
Authors | Kazuhiro Kasai, Yohei Kooka, Yuji Suzuki, Akiko Suzuki, Takayoshi Oikawa, Akira Ushio, Yukiho Kasai, Kei Sawara, Yasuhiro Miyamoto, Kanta Oikawa, Yasuhiro Takikawa |
Journal | Annals of surgical oncology
(Ann Surg Oncol)
Vol. 21
Issue 11
Pg. 3638-45
(Oct 2014)
ISSN: 1534-4681 [Electronic] United States |
PMID | 24817369
(Publication Type: Journal Article)
|
Chemical References |
- Antimetabolites, Antineoplastic
- Antiviral Agents
- Interferon alpha-2
- Interferon-alpha
- Recombinant Proteins
- Polyethylene Glycols
- peginterferon alfa-2b
- Fluorouracil
|
Topics |
- Adult
- Aged
- Antimetabolites, Antineoplastic
(therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
- Antiviral Agents
(therapeutic use)
- Bile Duct Neoplasms
(drug therapy, mortality, pathology)
- Bile Ducts, Intrahepatic
(pathology)
- Cholangiocarcinoma
(drug therapy, mortality, pathology)
- Female
- Fluorouracil
(therapeutic use)
- Follow-Up Studies
- Humans
- Infusions, Intra-Arterial
- Interferon alpha-2
- Interferon-alpha
(therapeutic use)
- Male
- Middle Aged
- Neoplasm Metastasis
- Neoplasm Staging
- Pilot Projects
- Polyethylene Glycols
(therapeutic use)
- Prognosis
- Recombinant Proteins
(therapeutic use)
- Survival Rate
|